Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 666 participants in total across several groups, all of whom had psoriasis. The trial was testing a medicine called CP-690,550 (also known as tofacitinib) at two different doses — 5 mg and 10 mg, taken twice daily. The study was designed in three phases: an initial treatment period (Period A), a withdrawal period where some participants were switched to a dummy tablet called a placebo (Period B), and a re-treatment period (Period C). The trial measured how participants' psoriasis responded using two scoring tools — the PASI score (a detailed measure of how much of the body is affected and how severe the patches are) and the PGA score (a doctor's overall rating from "clear" to "severe"). The reported data shows that during the withdrawal phase (Period B), among those who had been on the 5 mg dose, around 90% who stayed on the medicine still met the PASI75 response threshold (meaning their psoriasis score had dropped by at least 75% from the start) at an early time point, compared with about 63% of those switched to placebo; by a later time point in that period, those figures had dropped to roughly 63% and 32% respectively. Similar patterns were reported for the 10 mg group. For the doctor's overall rating (PGA), the reported data shows that around 81% of those continuing on 5 mg were rated "clear" or "almost clear" at an early point in Period B, compared with about 57% on placebo; for the 10 mg group the figures were approximately 80% versus 52%. The reported data also shows that during re-treatment (Period C), participants who had previously been on the 10 mg dose and were then switched back after a break reached response thresholds at higher rates over time than those re-starting the 5 mg dose. For the secondary outcomes, the median time reported to reach the PASI75 threshold during the first treatment period was approximately 24.3 weeks for the 5 mg group and 8.7 weeks for the 10 mg group; similarly, the median time to a "clear" or "almost clear" doctor rating was about 24.1 weeks for the 5 mg group and 8.1 weeks for the 10 mg group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 32816215) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- You are 18 years old or older and have been diagnosed with the most common form of psoriasis (called plaque psoriasis) for at least 12 months before starting the study
- Your psoriasis has been rated as moderate or severe by a doctor, based on standard scoring measurements
- Your psoriasis covers at least 10% of your body surface area
- You do not have an active, hidden, or untreated tuberculosis infection or other serious infections
Who may not be able to join:
- You have a less common type of psoriasis, or your psoriasis was caused by a medication
- You are unable to stop your current psoriasis treatments, including tablets, injections, creams, or light therapy, before and during the trial
- You have any serious medical condition that is not well controlled (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B); Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B); Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B); Percentage of Participants Achieving a PGA Response of Clear...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.